Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilocarpine - AbbVie

Next Previous
Search
Drug Profile

Pilocarpine - AbbVie

Alternative Names: AGN-190584; pilocarpine 1.25%; Pilocarpine 1.25% ophthalmic solution - AbbVie; Pilocarpine HCl 1.25%; VUITY

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allergan
  • Developer AbbVie; Allergan
  • Class Alkaloids; Antiglaucomas; Eye disorder therapies; Furans; Imidazoles; Ketones; Miotics; Small molecules
  • Mechanism of Action Muscarinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Presbyopia

Most Recent Events

  • 29 Jun 2022 Allergan withdraws a phase II ARIES trial for Presbyopia in USA (Ophthalmic, Drops) (NCT05393089)
  • 23 May 2022 Allergan plans a phase II ARIES trial for Presbyopia in USA (Ophthalmic, Drops) (NCT05393089)
  • 05 Apr 2022 Allergan announces intention to submit sNDA to US FDA for Presbyopia in in the second quarter of 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top